Director, See Remarks · Arcutis Biotherapeutics, Inc. · Common Stock
Side
SELL
Value
$75K
Shares
3,172
Price
$23.61
Executed
May 4, 2026
Disclosed
May 6, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
May 4 executedMay 6, 2026 disclosed
ARQT · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+4 / 15
2 prior trades recorded in this security
Frequency & clustering+10 / 15
2 other actors traded the same direction within 14 days
Market events0 / 10
No material company filing within 60 days after the trade
Pre-arranged plan-10
Executed under a Rule 10b5-1 trading plan
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Watanabe Todd filed this Form 4 reporting a open-market sale of ARQT on May 4, 2026. It became public on May 6, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director, See Remarks
Watanabe Toddcik:0001801061
Issuer
Arcutis Biotherapeutics, Inc.cik:0001787306
Revision history · 0
No field has changed since this record was first ingested.
